MAPT and Alzheimer disease: Our study confirmed that oral cerebroprotein hydrolysate can effectively improve the learning and memory function of AD mice, delay neuronal damage in the hippocampus, limit the accumulation of Aβ protein, and downregulate the p-tau/tau ratio.